apramycin
Small moleculeexperimental
Apramycin is an aminoglycoside antibiotic used in veterinary medicine. It is produced by Streptomyces tenebrarius. — Wikipedia
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 25, 2019 (NCT04105205)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- 30S ribosomal protein S12INHIBITOR
rpsL inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN[C@@H]1[C@@H](O[C@H]2O[C@H](CO)[C@@H](N)[C@H](O)[C@H]2O)OC2C[C@@H](N)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N)C[C@@H]3N)OC2[C@@H]1O- Mol. weight
- 539.58 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaApramycin ↗
- ChEMBLCHEMBL1909452 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05590728 | Phase 1 | Jan 9, 2023 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT04105205 | Phase 1 | Sep 25, 2019 | CRS Clinical Research Services Kiel GmbH, European Commission, Juvabis AG |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CRS Clinical Research Services Kiel GmbH | For profit | 1 | 0 | 1 | 2019 |
| European Commission | Government | 1 | 0 | 1 | 2019 |
| Juvabis AG | For profit | 1 | 1 | 1 | 2019 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1